Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News EuroPCR 2025

Early TAVI Improves Prognosis in Asymptomatic AS No Matter the Extent of Cardiac Damage

Yael L. Maxwell

May 21, 2025

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

News Conference News EuroPCR 2022

Changes in Cardiac Damage After AVR Tied to 2-Year Outcomes

Caitlin E. Cox

May 17, 2022

News Conference News EuroPCR 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Shelley Wood

May 23, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

Presentation EuroPCR 2017

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Presenter: Lucas Boersma, Martin W. Bergmann

May 18, 2017

Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve The ARTE Randomized Clinical Trial

Presentation EuroPCR 2017

The ARTE Randomized Clinical Trial

Presenter: Josep Rodés-Cabau

May 17, 2017

News Conference News EuroPCR 2016

Closer Look at Effects of CAD on TAVR Outcomes Unearths Grim Prognosis

Yael L. Maxwell

May 19, 2016

Advertisement

Early TAVI Improves Prognosis in Asymptomatic AS No Matter the Extent of Cardiac Damage

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Changes in Cardiac Damage After AVR Tied to 2-Year Outcomes

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

The ARTE Randomized Clinical Trial

Closer Look at Effects of CAD on TAVR Outcomes Unearths Grim Prognosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content